CRX-526

aminoalkyl-glucosaminide-phosphate; lipid A-mimetic with anti-inflammatory properties; structure in first source

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

1.	Endotoxemia 09/01/2015 - "The TLR4 pathway may be a target in clinical Gram-negative sepsis since administration of the TLR4 antagonist CRX-526 improved intestinal microcirculation parameters in experimental endotoxemia."
2.	Sepsis (Septicemia) 09/01/2015 - "The TLR4 pathway may be a target in clinical Gram-negative sepsis since administration of the TLR4 antagonist CRX-526 improved intestinal microcirculation parameters in experimental endotoxemia."
3.	Neoplasms (Cancer) 01/01/2014 - "TLR4 inhibition was also effective in the nude mouse xenograft model, as tumor sizes were significantly smaller, and expressions of TLR4 and NF-κB significantly lower, in the mice treated with CRX-526. "
4.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/15/2005 - "By blocking the interaction between enteric bacteria and the innate immune system, CRX-526 may be an effective therapeutic molecule for inflammatory bowel disease."
5.	Wounds and Injuries (Trauma) 05/01/2013 - "Here we explored whether the TLR4 antagonist, CRX-526, has therapeutic potential to attenuate renal injuries and slow the progression of advanced diabetic nephropathy in wild-type and endothelial nitric oxide synthase (eNOS) knockout mice. "

1.	Osteopontin
2.	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
3.	CC Chemokines
4.	Urea (Carbamide)
5.	Nitrogen
6.	Ligands
7.	Dextrans (Dextran)
8.	Collagen
9.	Blood Glucose (Blood Sugar)
10.	sodium sulfate (sodium bisulfate)